NEW YORK (GenomeWeb) – Cellecta announced today that it has been awarded a Phase II SBIR grant from the National Institutes of Health to complete development of a genome-wide CRISPR/Cas9 screening platform that it aims to commercialize by late 2018.

CRISPR/Cas9 involves the use of an enzyme to cause double-strand DNA breaks that induce gene silencing. The process can be targeted to specific areas of the genome using so-called single guide RNAs (sgRNAs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers in China have generated mouse pups from same-sex parents, according to Scientific American.

Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.

The South China Morning Post reports that Hong Kong plans to add HK$20 billion (US$2.6 billion) to a research endowment.

In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.